Shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) rose 0.7% during mid-day trading on Monday . The company traded as high as $1.61 and last traded at $1.42. Approximately 376,116 shares were traded during mid-day trading, an increase of 262% from the average daily volume of 103,829 shares. The stock had previously closed at $1.41.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genenta Science in a research report on Monday, December 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
Get Our Latest Research Report on GNTA
Genenta Science Price Performance
Genenta Science (NASDAQ:GNTA – Get Free Report) last announced its quarterly earnings results on Friday, October 10th. The company reported ($0.10) earnings per share for the quarter. Analysts anticipate that Genenta Science S.p.A. Unsponsored ADR will post -0.93 earnings per share for the current fiscal year.
Institutional Trading of Genenta Science
A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC acquired a new stake in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned approximately 0.07% of Genenta Science as of its most recent SEC filing. Institutional investors own 15.13% of the company’s stock.
Genenta Science Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
See Also
- Five stocks we like better than Genenta Science
- Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- What is the S&P/TSX Index?
- Dell and HP Are Raising Prices—And Investors Should Take Note
- What Does a Stock Split Mean?
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
